Colin Walsh - SEC Form 4 Insider Trading Activity
Director
Summary
Updated Aug 16, 2026
Colin Walsh has filed 1 SEC Form 4 filing across 1 company in the last 90 days - active on both sides. Lifetime open-market purchases: $10.29M. Lifetime open-market sales: $2.25M.
Trading Pattern
InsiderAlpha's records for Colin Walsh go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. The typical open-market purchase is $5.14M (2 buys totaling $10.29M). The largest single buy on record is $8.50M of ATTO in 2026. Sales side: 23 recorded sales totaling $2.25M, so the filing history runs buy-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Colin Walsh has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director at Attovia Therapeutics, Inc. (ATTO) - 1 filing, 2026
Recent Transactions
20Companies - Last 90 Days
1- Attovia Therapeutics, Inc. (ATTO) - 1 filing, last 2026-08-14
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Colin Walsh has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- GOLDMAN SACHS GROUP INC - $12.54M of ATTO open-market activity in the last 12 months
- Redmile Group, LLC - $10.20M of ATTO open-market activity in the last 12 months
- Frazier Life Sciences XI, L.P. - $10.00M of ATTO open-market activity in the last 12 months
- venBio Global Strategic Fund IV, L.P. - $6.50M of ATTO open-market activity in the last 12 months
- Sanofi - $5.10M of ATTO open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Colin Walsh?
Colin Walsh is a corporate insider - currently tracked as Director of Attovia Therapeutics, Inc. (ATTO). InsiderAlpha tracks every SEC Form 4 filing in real time.
How many SEC Form 4 filings has Colin Walsh submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Colin Walsh been buying or selling stock?
Recorded transactions: 2 open-market purchases ($10.29M) and 23 open-market sales ($2.25M) across all tracked filings.
Where can I see all of Colin Walsh's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Get alerts when Colin Walsh files a new Form 4
Track every insider buy in real time, with AI-scored daily trade ideas and 10b5-1 plan flags.
Free during early access · No credit card required